nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—OPRM1—telencephalic ventricle—malignant glioma	0.0259	0.252	CbGeAlD
Naltrexone—Haemorrhoids—Temozolomide—malignant glioma	0.0143	0.0223	CcSEcCtD
Naltrexone—Deep vein thrombosis—Temozolomide—malignant glioma	0.0138	0.0215	CcSEcCtD
Naltrexone—Paranoia—Carmustine—malignant glioma	0.0128	0.0199	CcSEcCtD
Naltrexone—Hepatotoxicity—Carmustine—malignant glioma	0.0113	0.0176	CcSEcCtD
Naltrexone—Hepatotoxicity—Temozolomide—malignant glioma	0.0109	0.017	CcSEcCtD
Naltrexone—Injection site pain—Carmustine—malignant glioma	0.0107	0.0166	CcSEcCtD
Naltrexone—Rigors—Temozolomide—malignant glioma	0.0103	0.016	CcSEcCtD
Naltrexone—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.0102	0.0159	CcSEcCtD
Naltrexone—Disturbance in attention—Temozolomide—malignant glioma	0.00972	0.0151	CcSEcCtD
Naltrexone—Thinking abnormal—Carmustine—malignant glioma	0.00952	0.0148	CcSEcCtD
Naltrexone—OPRD1—telencephalon—malignant glioma	0.00911	0.0886	CbGeAlD
Naltrexone—Hepatic enzyme increased—Temozolomide—malignant glioma	0.0089	0.0138	CcSEcCtD
Naltrexone—Buprenorphine—CYP2C18—malignant glioma	0.00877	0.675	CrCbGaD
Naltrexone—Pulmonary embolism—Carmustine—malignant glioma	0.00871	0.0136	CcSEcCtD
Naltrexone—Injection site reaction—Carmustine—malignant glioma	0.00866	0.0135	CcSEcCtD
Naltrexone—Pulmonary embolism—Temozolomide—malignant glioma	0.00842	0.0131	CcSEcCtD
Naltrexone—Mental disability—Carmustine—malignant glioma	0.00756	0.0118	CcSEcCtD
Naltrexone—Phlebitis—Carmustine—malignant glioma	0.00734	0.0114	CcSEcCtD
Naltrexone—Mental disability—Temozolomide—malignant glioma	0.0073	0.0114	CcSEcCtD
Naltrexone—Swelling—Carmustine—malignant glioma	0.00717	0.0112	CcSEcCtD
Naltrexone—OPRM1—brainstem—malignant glioma	0.007	0.0681	CbGeAlD
Naltrexone—Gastroenteritis—Temozolomide—malignant glioma	0.00689	0.0107	CcSEcCtD
Naltrexone—Nasal congestion—Temozolomide—malignant glioma	0.00671	0.0104	CcSEcCtD
Naltrexone—Hot flush—Temozolomide—malignant glioma	0.00653	0.0102	CcSEcCtD
Naltrexone—Menopausal symptoms—Temozolomide—malignant glioma	0.00648	0.0101	CcSEcCtD
Naltrexone—Thirst—Temozolomide—malignant glioma	0.00642	0.00999	CcSEcCtD
Naltrexone—Purpura—Temozolomide—malignant glioma	0.00634	0.00986	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00632	0.00984	CcSEcCtD
Naltrexone—OPRM1—telencephalon—malignant glioma	0.00621	0.0604	CbGeAlD
Naltrexone—Face oedema—Carmustine—malignant glioma	0.0061	0.0095	CcSEcCtD
Naltrexone—Face oedema—Temozolomide—malignant glioma	0.0059	0.00918	CcSEcCtD
Naltrexone—Dehydration—Temozolomide—malignant glioma	0.00568	0.00884	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.0055	0.00856	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00539	0.00838	CcSEcCtD
Naltrexone—OPRD1—central nervous system—malignant glioma	0.00518	0.0504	CbGeAlD
Naltrexone—Sweating increased—Temozolomide—malignant glioma	0.00514	0.008	CcSEcCtD
Naltrexone—Bronchitis—Temozolomide—malignant glioma	0.00508	0.0079	CcSEcCtD
Naltrexone—OPRK1—central nervous system—malignant glioma	0.00496	0.0483	CbGeAlD
Naltrexone—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00491	0.00764	CcSEcCtD
Naltrexone—Pneumonia—Carmustine—malignant glioma	0.0049	0.00763	CcSEcCtD
Naltrexone—Depression—Carmustine—malignant glioma	0.00486	0.00756	CcSEcCtD
Naltrexone—OPRK1—cerebellum—malignant glioma	0.00485	0.0472	CbGeAlD
Naltrexone—Weight increased—Temozolomide—malignant glioma	0.00481	0.00748	CcSEcCtD
Naltrexone—Weight decreased—Temozolomide—malignant glioma	0.00478	0.00743	CcSEcCtD
Naltrexone—Urinary tract infection—Carmustine—malignant glioma	0.00474	0.00737	CcSEcCtD
Naltrexone—Pneumonia—Temozolomide—malignant glioma	0.00474	0.00737	CcSEcCtD
Naltrexone—Infestation NOS—Temozolomide—malignant glioma	0.00471	0.00733	CcSEcCtD
Naltrexone—Infestation—Temozolomide—malignant glioma	0.00471	0.00733	CcSEcCtD
Naltrexone—Depression—Temozolomide—malignant glioma	0.0047	0.00731	CcSEcCtD
Naltrexone—Urinary tract infection—Temozolomide—malignant glioma	0.00458	0.00712	CcSEcCtD
Naltrexone—OPRM1—midbrain—malignant glioma	0.00446	0.0434	CbGeAlD
Naltrexone—Hepatobiliary disease—Temozolomide—malignant glioma	0.00445	0.00693	CcSEcCtD
Naltrexone—Sinusitis—Temozolomide—malignant glioma	0.00442	0.00687	CcSEcCtD
Naltrexone—Hallucination—Carmustine—malignant glioma	0.00435	0.00677	CcSEcCtD
Naltrexone—OPRM1—spinal cord—malignant glioma	0.00435	0.0424	CbGeAlD
Naltrexone—Connective tissue disorder—Carmustine—malignant glioma	0.0043	0.00669	CcSEcCtD
Naltrexone—Hepatitis—Temozolomide—malignant glioma	0.00423	0.00658	CcSEcCtD
Naltrexone—Hydromorphone—PTGS1—malignant glioma	0.00422	0.325	CrCbGaD
Naltrexone—Hallucination—Temozolomide—malignant glioma	0.00421	0.00654	CcSEcCtD
Naltrexone—Pharyngitis—Temozolomide—malignant glioma	0.0042	0.00653	CcSEcCtD
Naltrexone—Connective tissue disorder—Temozolomide—malignant glioma	0.00415	0.00646	CcSEcCtD
Naltrexone—OPRD1—brain—malignant glioma	0.00411	0.04	CbGeAlD
Naltrexone—Eye disorder—Carmustine—malignant glioma	0.00409	0.00636	CcSEcCtD
Naltrexone—Eye disorder—Temozolomide—malignant glioma	0.00395	0.00615	CcSEcCtD
Naltrexone—Tinnitus—Temozolomide—malignant glioma	0.00394	0.00613	CcSEcCtD
Naltrexone—OPRK1—brain—malignant glioma	0.00394	0.0383	CbGeAlD
Naltrexone—Cardiac disorder—Temozolomide—malignant glioma	0.00392	0.0061	CcSEcCtD
Naltrexone—Alopecia—Carmustine—malignant glioma	0.00387	0.00601	CcSEcCtD
Naltrexone—Angiopathy—Temozolomide—malignant glioma	0.00384	0.00597	CcSEcCtD
Naltrexone—Mental disorder—Carmustine—malignant glioma	0.00383	0.00596	CcSEcCtD
Naltrexone—Immune system disorder—Temozolomide—malignant glioma	0.00382	0.00594	CcSEcCtD
Naltrexone—Mediastinal disorder—Temozolomide—malignant glioma	0.00381	0.00593	CcSEcCtD
Naltrexone—Malnutrition—Carmustine—malignant glioma	0.00381	0.00592	CcSEcCtD
Naltrexone—Chills—Temozolomide—malignant glioma	0.00379	0.0059	CcSEcCtD
Naltrexone—Alopecia—Temozolomide—malignant glioma	0.00374	0.00581	CcSEcCtD
Naltrexone—Mental disorder—Temozolomide—malignant glioma	0.0037	0.00576	CcSEcCtD
Naltrexone—ABCB1—blood vessel—malignant glioma	0.00369	0.0359	CbGeAlD
Naltrexone—Back pain—Carmustine—malignant glioma	0.00368	0.00573	CcSEcCtD
Naltrexone—Malnutrition—Temozolomide—malignant glioma	0.00368	0.00573	CcSEcCtD
Naltrexone—Dysgeusia—Temozolomide—malignant glioma	0.0036	0.00561	CcSEcCtD
Naltrexone—Vision blurred—Carmustine—malignant glioma	0.00359	0.00558	CcSEcCtD
Naltrexone—Tremor—Carmustine—malignant glioma	0.00357	0.00555	CcSEcCtD
Naltrexone—Back pain—Temozolomide—malignant glioma	0.00356	0.00554	CcSEcCtD
Naltrexone—OPRM1—central nervous system—malignant glioma	0.00353	0.0344	CbGeAlD
Naltrexone—Agitation—Carmustine—malignant glioma	0.0035	0.00544	CcSEcCtD
Naltrexone—Vision blurred—Temozolomide—malignant glioma	0.00347	0.0054	CcSEcCtD
Naltrexone—Tremor—Temozolomide—malignant glioma	0.00345	0.00536	CcSEcCtD
Naltrexone—Ill-defined disorder—Temozolomide—malignant glioma	0.00341	0.00531	CcSEcCtD
Naltrexone—Agitation—Temozolomide—malignant glioma	0.00338	0.00526	CcSEcCtD
Naltrexone—Angioedema—Temozolomide—malignant glioma	0.00336	0.00523	CcSEcCtD
Naltrexone—Malaise—Temozolomide—malignant glioma	0.00332	0.00516	CcSEcCtD
Naltrexone—Convulsion—Carmustine—malignant glioma	0.0033	0.00513	CcSEcCtD
Naltrexone—Hypertension—Carmustine—malignant glioma	0.00329	0.00511	CcSEcCtD
Naltrexone—Palpitations—Temozolomide—malignant glioma	0.00325	0.00506	CcSEcCtD
Naltrexone—Myalgia—Carmustine—malignant glioma	0.00324	0.00504	CcSEcCtD
Naltrexone—Chest pain—Carmustine—malignant glioma	0.00324	0.00504	CcSEcCtD
Naltrexone—Anxiety—Carmustine—malignant glioma	0.00323	0.00503	CcSEcCtD
Naltrexone—Cough—Temozolomide—malignant glioma	0.00321	0.005	CcSEcCtD
Naltrexone—Convulsion—Temozolomide—malignant glioma	0.00319	0.00496	CcSEcCtD
Naltrexone—Hypertension—Temozolomide—malignant glioma	0.00318	0.00494	CcSEcCtD
Naltrexone—Confusional state—Carmustine—malignant glioma	0.00313	0.00488	CcSEcCtD
Naltrexone—Arthralgia—Temozolomide—malignant glioma	0.00313	0.00487	CcSEcCtD
Naltrexone—Myalgia—Temozolomide—malignant glioma	0.00313	0.00487	CcSEcCtD
Naltrexone—Anxiety—Temozolomide—malignant glioma	0.00312	0.00486	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00311	0.00484	CcSEcCtD
Naltrexone—Oedema—Carmustine—malignant glioma	0.00311	0.00484	CcSEcCtD
Naltrexone—Discomfort—Temozolomide—malignant glioma	0.0031	0.00482	CcSEcCtD
Naltrexone—Infection—Carmustine—malignant glioma	0.00309	0.0048	CcSEcCtD
Naltrexone—Dry mouth—Temozolomide—malignant glioma	0.00306	0.00477	CcSEcCtD
Naltrexone—Tachycardia—Carmustine—malignant glioma	0.00303	0.00472	CcSEcCtD
Naltrexone—Confusional state—Temozolomide—malignant glioma	0.00303	0.00471	CcSEcCtD
Naltrexone—Anaphylactic shock—Temozolomide—malignant glioma	0.003	0.00467	CcSEcCtD
Naltrexone—Oedema—Temozolomide—malignant glioma	0.003	0.00467	CcSEcCtD
Naltrexone—Infection—Temozolomide—malignant glioma	0.00298	0.00464	CcSEcCtD
Naltrexone—Anorexia—Carmustine—malignant glioma	0.00296	0.00461	CcSEcCtD
Naltrexone—Nervous system disorder—Temozolomide—malignant glioma	0.00295	0.00458	CcSEcCtD
Naltrexone—Skin disorder—Temozolomide—malignant glioma	0.00292	0.00454	CcSEcCtD
Naltrexone—Hyperhidrosis—Temozolomide—malignant glioma	0.0029	0.00452	CcSEcCtD
Naltrexone—Anorexia—Temozolomide—malignant glioma	0.00286	0.00445	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00283	0.00441	CcSEcCtD
Naltrexone—Insomnia—Carmustine—malignant glioma	0.00281	0.00437	CcSEcCtD
Naltrexone—OPRM1—brain—malignant glioma	0.0028	0.0273	CbGeAlD
Naltrexone—Paraesthesia—Carmustine—malignant glioma	0.00279	0.00434	CcSEcCtD
Naltrexone—Dyspnoea—Carmustine—malignant glioma	0.00277	0.00431	CcSEcCtD
Naltrexone—Somnolence—Carmustine—malignant glioma	0.00276	0.0043	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00274	0.00426	CcSEcCtD
Naltrexone—Insomnia—Temozolomide—malignant glioma	0.00272	0.00423	CcSEcCtD
Naltrexone—Decreased appetite—Carmustine—malignant glioma	0.0027	0.0042	CcSEcCtD
Naltrexone—Paraesthesia—Temozolomide—malignant glioma	0.0027	0.0042	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Carmustine—malignant glioma	0.00268	0.00417	CcSEcCtD
Naltrexone—Dyspnoea—Temozolomide—malignant glioma	0.00268	0.00417	CcSEcCtD
Naltrexone—Somnolence—Temozolomide—malignant glioma	0.00267	0.00415	CcSEcCtD
Naltrexone—Pain—Carmustine—malignant glioma	0.00266	0.00413	CcSEcCtD
Naltrexone—Constipation—Carmustine—malignant glioma	0.00266	0.00413	CcSEcCtD
Naltrexone—Decreased appetite—Temozolomide—malignant glioma	0.00261	0.00406	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00259	0.00403	CcSEcCtD
Naltrexone—Fatigue—Temozolomide—malignant glioma	0.00259	0.00403	CcSEcCtD
Naltrexone—Pain—Temozolomide—malignant glioma	0.00257	0.004	CcSEcCtD
Naltrexone—Constipation—Temozolomide—malignant glioma	0.00257	0.004	CcSEcCtD
Naltrexone—Feeling abnormal—Carmustine—malignant glioma	0.00256	0.00398	CcSEcCtD
Naltrexone—Gastrointestinal pain—Carmustine—malignant glioma	0.00254	0.00395	CcSEcCtD
Naltrexone—Feeling abnormal—Temozolomide—malignant glioma	0.00247	0.00385	CcSEcCtD
Naltrexone—Body temperature increased—Carmustine—malignant glioma	0.00246	0.00382	CcSEcCtD
Naltrexone—Abdominal pain—Carmustine—malignant glioma	0.00246	0.00382	CcSEcCtD
Naltrexone—Gastrointestinal pain—Temozolomide—malignant glioma	0.00246	0.00382	CcSEcCtD
Naltrexone—Urticaria—Temozolomide—malignant glioma	0.00239	0.00371	CcSEcCtD
Naltrexone—Body temperature increased—Temozolomide—malignant glioma	0.00237	0.00369	CcSEcCtD
Naltrexone—Abdominal pain—Temozolomide—malignant glioma	0.00237	0.00369	CcSEcCtD
Naltrexone—Hypersensitivity—Carmustine—malignant glioma	0.00229	0.00356	CcSEcCtD
Naltrexone—Asthenia—Carmustine—malignant glioma	0.00223	0.00347	CcSEcCtD
Naltrexone—Hypersensitivity—Temozolomide—malignant glioma	0.00221	0.00344	CcSEcCtD
Naltrexone—ABCB1—embryo—malignant glioma	0.0022	0.0214	CbGeAlD
Naltrexone—Asthenia—Temozolomide—malignant glioma	0.00215	0.00335	CcSEcCtD
Naltrexone—Diarrhoea—Carmustine—malignant glioma	0.00213	0.00331	CcSEcCtD
Naltrexone—Pruritus—Temozolomide—malignant glioma	0.00212	0.00331	CcSEcCtD
Naltrexone—Dizziness—Carmustine—malignant glioma	0.00206	0.0032	CcSEcCtD
Naltrexone—Diarrhoea—Temozolomide—malignant glioma	0.00205	0.0032	CcSEcCtD
Naltrexone—Dizziness—Temozolomide—malignant glioma	0.00199	0.00309	CcSEcCtD
Naltrexone—Vomiting—Carmustine—malignant glioma	0.00198	0.00307	CcSEcCtD
Naltrexone—Rash—Carmustine—malignant glioma	0.00196	0.00305	CcSEcCtD
Naltrexone—Dermatitis—Carmustine—malignant glioma	0.00196	0.00305	CcSEcCtD
Naltrexone—ABCB1—retina—malignant glioma	0.00195	0.019	CbGeAlD
Naltrexone—Headache—Carmustine—malignant glioma	0.00195	0.00303	CcSEcCtD
Naltrexone—Vomiting—Temozolomide—malignant glioma	0.00191	0.00297	CcSEcCtD
Naltrexone—Rash—Temozolomide—malignant glioma	0.00189	0.00295	CcSEcCtD
Naltrexone—Dermatitis—Temozolomide—malignant glioma	0.00189	0.00294	CcSEcCtD
Naltrexone—Headache—Temozolomide—malignant glioma	0.00188	0.00293	CcSEcCtD
Naltrexone—Nausea—Carmustine—malignant glioma	0.00185	0.00287	CcSEcCtD
Naltrexone—ABCB1—telencephalon—malignant glioma	0.00179	0.0174	CbGeAlD
Naltrexone—Nausea—Temozolomide—malignant glioma	0.00178	0.00278	CcSEcCtD
Naltrexone—ABCB1—medulla oblongata—malignant glioma	0.00141	0.0137	CbGeAlD
Naltrexone—ABCB1—midbrain—malignant glioma	0.00129	0.0125	CbGeAlD
Naltrexone—ABCB1—spinal cord—malignant glioma	0.00125	0.0122	CbGeAlD
Naltrexone—ABCB1—central nervous system—malignant glioma	0.00102	0.00991	CbGeAlD
Naltrexone—ABCB1—cerebellum—malignant glioma	0.000995	0.00968	CbGeAlD
Naltrexone—ABCB1—brain—malignant glioma	0.000808	0.00787	CbGeAlD
Naltrexone—OPRK1—Signaling Pathways—FBXW7—malignant glioma	0.000163	0.000673	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	0.000161	0.000668	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BDKRB2—malignant glioma	0.000159	0.00066	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—F2—malignant glioma	0.000159	0.000657	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT2—malignant glioma	0.000158	0.000656	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NTRK1—malignant glioma	0.000158	0.000653	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000157	0.000651	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT2—malignant glioma	0.000153	0.000634	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CD—malignant glioma	0.000152	0.000631	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CG—malignant glioma	0.000152	0.000629	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	0.000151	0.000627	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PTPN11—malignant glioma	0.000149	0.000618	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—H3F3A—malignant glioma	0.000149	0.000616	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH2—malignant glioma	0.000148	0.000614	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—F2—malignant glioma	0.000148	0.000612	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR3—malignant glioma	0.000147	0.00061	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CD—malignant glioma	0.000147	0.000609	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP3—malignant glioma	0.000147	0.000607	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000146	0.000605	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN2B—malignant glioma	0.000145	0.000602	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KNG1—malignant glioma	0.000145	0.000601	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK2—malignant glioma	0.000143	0.000593	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—YWHAE—malignant glioma	0.000143	0.000593	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FLT1—malignant glioma	0.000143	0.000591	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—DUSP6—malignant glioma	0.000142	0.000588	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CG—malignant glioma	0.000141	0.000585	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTK2—malignant glioma	0.000141	0.000584	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—malignant glioma	0.00014	0.000582	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAG1—malignant glioma	0.00014	0.000581	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH3—malignant glioma	0.00014	0.000578	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT2—malignant glioma	0.000139	0.000575	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HES1—malignant glioma	0.000139	0.000574	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NTRK1—malignant glioma	0.000138	0.000572	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NCOR1—malignant glioma	0.000138	0.000571	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FBXW7—malignant glioma	0.000137	0.000569	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	0.000137	0.000567	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—IDH2—malignant glioma	0.000136	0.000565	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RAF1—malignant glioma	0.000136	0.000563	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—malignant glioma	0.000136	0.000563	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BDKRB2—malignant glioma	0.000135	0.000558	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—malignant glioma	0.000134	0.000556	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—F2—malignant glioma	0.000134	0.000555	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CD—malignant glioma	0.000134	0.000553	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CB—malignant glioma	0.000133	0.00055	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAT—malignant glioma	0.000132	0.000548	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDGFRA—malignant glioma	0.000132	0.000546	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT2—malignant glioma	0.000129	0.000536	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP3—malignant glioma	0.000129	0.000532	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CG—malignant glioma	0.000128	0.000532	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2B6—malignant glioma	0.000128	0.000531	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000128	0.000531	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SPP1—malignant glioma	0.000128	0.00053	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—malignant glioma	0.000128	0.000528	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN2B—malignant glioma	0.000127	0.000528	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PTPN11—malignant glioma	0.000126	0.000522	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	0.000126	0.000521	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH2—malignant glioma	0.000125	0.000519	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NCOR1—malignant glioma	0.000125	0.000517	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CD—malignant glioma	0.000124	0.000515	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTK2—malignant glioma	0.000124	0.000512	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—malignant glioma	0.000123	0.00051	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	0.000123	0.00051	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KNG1—malignant glioma	0.000123	0.000508	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—malignant glioma	0.000122	0.000505	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HES1—malignant glioma	0.000122	0.000503	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—malignant glioma	0.000121	0.000503	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NCOR1—malignant glioma	0.000121	0.0005	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAF1—malignant glioma	0.000119	0.000494	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PDGFB—malignant glioma	0.000119	0.000491	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGFR1—malignant glioma	0.000118	0.000488	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—malignant glioma	0.000118	0.000487	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT2—malignant glioma	0.000117	0.000486	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—IDH1—malignant glioma	0.000117	0.000486	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	0.000117	0.000486	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NTRK1—malignant glioma	0.000117	0.000484	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CB—malignant glioma	0.000116	0.000482	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	0.000116	0.000482	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—malignant glioma	0.000116	0.000481	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFRA—malignant glioma	0.000116	0.000479	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SPHK1—malignant glioma	0.000114	0.00047	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—malignant glioma	0.000113	0.000467	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SPP1—malignant glioma	0.000112	0.000465	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—malignant glioma	0.000112	0.000465	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—malignant glioma	0.000112	0.000463	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2C18—malignant glioma	0.000111	0.000461	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—malignant glioma	0.000111	0.00046	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP3—malignant glioma	0.000109	0.00045	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000108	0.000449	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN2B—malignant glioma	0.000108	0.000446	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—F2—malignant glioma	0.000107	0.000443	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FN1—malignant glioma	0.000107	0.000443	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—malignant glioma	0.000107	0.000443	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	0.000107	0.000442	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—malignant glioma	0.000106	0.000441	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BAD—malignant glioma	0.000106	0.000437	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOTCH1—malignant glioma	0.000105	0.000433	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTK2—malignant glioma	0.000105	0.000433	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—malignant glioma	0.000104	0.000431	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PDGFB—malignant glioma	0.000104	0.00043	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR1—malignant glioma	0.000103	0.000428	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	0.000103	0.000428	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HES1—malignant glioma	0.000103	0.000425	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD80—malignant glioma	0.000103	0.000424	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—malignant glioma	0.000102	0.000424	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—malignant glioma	0.000102	0.000424	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCOR1—malignant glioma	0.000102	0.000423	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—malignant glioma	0.000102	0.000422	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—malignant glioma	0.000102	0.000422	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—malignant glioma	0.000101	0.000419	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—malignant glioma	0.000101	0.000417	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTPN11—malignant glioma	0.000101	0.000416	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—malignant glioma	9.95e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—malignant glioma	9.85e-05	0.000408	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—malignant glioma	9.84e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFRA—malignant glioma	9.78e-05	0.000405	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—malignant glioma	9.74e-05	0.000403	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—malignant glioma	9.62e-05	0.000398	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SPP1—malignant glioma	9.49e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—malignant glioma	9.45e-05	0.000391	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FN1—malignant glioma	9.38e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2—malignant glioma	9.38e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT2—malignant glioma	9.36e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—malignant glioma	9.32e-05	0.000386	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—malignant glioma	9.27e-05	0.000384	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BAD—malignant glioma	9.26e-05	0.000384	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOTCH1—malignant glioma	9.18e-05	0.00038	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—malignant glioma	9.03e-05	0.000374	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—malignant glioma	9e-05	0.000373	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—malignant glioma	9e-05	0.000372	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—malignant glioma	9e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD80—malignant glioma	8.99e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—malignant glioma	8.97e-05	0.000372	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—malignant glioma	8.97e-05	0.000372	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—malignant glioma	8.95e-05	0.000371	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—malignant glioma	8.91e-05	0.000369	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—malignant glioma	8.87e-05	0.000367	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTPN11—malignant glioma	8.82e-05	0.000365	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—malignant glioma	8.81e-05	0.000365	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFB—malignant glioma	8.78e-05	0.000364	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR1—malignant glioma	8.74e-05	0.000362	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	8.73e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—malignant glioma	8.61e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—malignant glioma	8.61e-05	0.000356	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—malignant glioma	8.43e-05	0.000349	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS1—malignant glioma	8.43e-05	0.000349	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—malignant glioma	8.33e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—malignant glioma	8.23e-05	0.000341	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT2—malignant glioma	8.21e-05	0.00034	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—malignant glioma	8.17e-05	0.000338	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—malignant glioma	8.15e-05	0.000338	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—malignant glioma	8.09e-05	0.000335	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—malignant glioma	8.06e-05	0.000334	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—malignant glioma	8.03e-05	0.000333	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—malignant glioma	7.95e-05	0.000329	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2—malignant glioma	7.92e-05	0.000328	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FN1—malignant glioma	7.92e-05	0.000328	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—malignant glioma	7.89e-05	0.000327	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—malignant glioma	7.84e-05	0.000325	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—BCHE—malignant glioma	7.84e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BAD—malignant glioma	7.83e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—malignant glioma	7.81e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOTCH1—malignant glioma	7.75e-05	0.000321	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A5—malignant glioma	7.74e-05	0.000321	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—malignant glioma	7.72e-05	0.00032	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD80—malignant glioma	7.6e-05	0.000315	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—malignant glioma	7.58e-05	0.000314	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—malignant glioma	7.58e-05	0.000314	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—malignant glioma	7.55e-05	0.000313	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—malignant glioma	7.53e-05	0.000312	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—malignant glioma	7.5e-05	0.00031	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTPN11—malignant glioma	7.45e-05	0.000308	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—malignant glioma	7.28e-05	0.000301	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—malignant glioma	7.21e-05	0.000299	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—malignant glioma	7.2e-05	0.000298	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	7.13e-05	0.000295	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—malignant glioma	7.13e-05	0.000295	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—malignant glioma	7.11e-05	0.000294	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—malignant glioma	7.09e-05	0.000294	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—malignant glioma	7.07e-05	0.000293	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—malignant glioma	7.04e-05	0.000292	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—malignant glioma	7.04e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—malignant glioma	6.97e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT2—malignant glioma	6.94e-05	0.000287	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—malignant glioma	6.91e-05	0.000286	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—malignant glioma	6.88e-05	0.000285	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—malignant glioma	6.82e-05	0.000282	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—malignant glioma	6.78e-05	0.000281	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—malignant glioma	6.67e-05	0.000276	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—malignant glioma	6.61e-05	0.000274	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—malignant glioma	6.61e-05	0.000274	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—malignant glioma	6.6e-05	0.000273	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—malignant glioma	6.53e-05	0.00027	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—malignant glioma	6.38e-05	0.000264	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—malignant glioma	6.38e-05	0.000264	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—malignant glioma	6.32e-05	0.000262	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—malignant glioma	6.31e-05	0.000261	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—malignant glioma	6.24e-05	0.000258	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—malignant glioma	6.14e-05	0.000254	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—malignant glioma	6.12e-05	0.000253	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAT—malignant glioma	6.07e-05	0.000251	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—malignant glioma	6.06e-05	0.000251	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—malignant glioma	6e-05	0.000248	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—malignant glioma	5.98e-05	0.000247	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—malignant glioma	5.97e-05	0.000247	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—malignant glioma	5.95e-05	0.000246	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—malignant glioma	5.94e-05	0.000246	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—malignant glioma	5.89e-05	0.000244	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—malignant glioma	5.81e-05	0.000241	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—malignant glioma	5.8e-05	0.00024	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOR1—malignant glioma	5.73e-05	0.000237	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—malignant glioma	5.63e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—malignant glioma	5.58e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—malignant glioma	5.51e-05	0.000228	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—malignant glioma	5.39e-05	0.000223	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—malignant glioma	5.37e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—malignant glioma	5.34e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—malignant glioma	5.34e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—malignant glioma	5.31e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—malignant glioma	5.2e-05	0.000215	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—malignant glioma	5.05e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—malignant glioma	5.02e-05	0.000208	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—malignant glioma	4.94e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—malignant glioma	4.9e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—malignant glioma	4.83e-05	0.0002	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—malignant glioma	4.78e-05	0.000198	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—malignant glioma	4.67e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—malignant glioma	4.62e-05	0.000191	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—malignant glioma	4.56e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—malignant glioma	4.54e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—malignant glioma	4.49e-05	0.000186	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—malignant glioma	4.33e-05	0.000179	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—malignant glioma	4.25e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—malignant glioma	4.19e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—malignant glioma	4.17e-05	0.000173	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—malignant glioma	4.11e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—malignant glioma	4.08e-05	0.000169	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—malignant glioma	4.05e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—malignant glioma	3.9e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—malignant glioma	3.86e-05	0.00016	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—malignant glioma	3.74e-05	0.000155	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—malignant glioma	3.54e-05	0.000147	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—malignant glioma	3.54e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—malignant glioma	3.43e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—malignant glioma	3.42e-05	0.000142	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—malignant glioma	3.26e-05	0.000135	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—malignant glioma	3.23e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—malignant glioma	2.89e-05	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—malignant glioma	2.82e-05	0.000117	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—malignant glioma	1.99e-05	8.23e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—malignant glioma	1.62e-05	6.72e-05	CbGpPWpGaD
